uniQure (NASDAQ:QURE) Short Interest Update

uniQure (NASDAQ:QURE) was the recipient of a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 3,180,000 shares, a growth of 22.8% from the June 30th total of 2,590,000 shares. Based on an average daily trading volume, of 2,730,000 shares, the days-to-cover ratio is presently 1.2 days.

Institutional Trading of uniQure

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in uniQure in the fourth quarter worth approximately $116,000. Raymond James & Associates grew its holdings in shares of uniQure by 6.4% in the fourth quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock worth $354,000 after acquiring an additional 3,145 shares during the period. China Universal Asset Management Co. Ltd. increased its position in uniQure by 222.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 4,315 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in uniQure by 458.5% in the fourth quarter. Vontobel Holding Ltd. now owns 295,042 shares of the biotechnology company’s stock valued at $1,997,000 after acquiring an additional 242,214 shares during the period. Finally, abrdn plc purchased a new position in uniQure in the fourth quarter worth about $2,711,000. 78.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

QURE has been the topic of several research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, July 16th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of uniQure in a research report on Tuesday, July 9th. Finally, Mizuho reduced their price objective on uniQure from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.50.

uniQure Stock Down 2.7 %

QURE stock traded down $0.23 during midday trading on Friday, hitting $8.34. The company’s stock had a trading volume of 733,674 shares, compared to its average volume of 7,658,339. The firm’s 50-day moving average is $5.75 and its 200-day moving average is $5.48. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The company has a debt-to-equity ratio of 0.70, a quick ratio of 9.27 and a current ratio of 9.39.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. The business had revenue of $8.49 million for the quarter, compared to the consensus estimate of $2.58 million. On average, equities research analysts expect that uniQure will post -4.4 EPS for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.